RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure

RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

Story continues below

On December 10, 2018, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s Senior Vice President of Research and Development, Richard Purcell and its Senior Vice President, Chief Financial Officer, Treasurer and Secretary, Jeff E. Margolis, each will be presenting at the International Cannabinoid Derived Pharmaceuticals Summit at the Revere Hotel in Boston, Massachusetts. Mr. Purcell is scheduled to co-lead a pre-conference workshop on “Financial Planning and Commercial Strategy” on Monday, December 10, 2018. Mr. Purcell is also scheduled to present “Using Cannabis to Treat Previously Untreatable Diseases” on Wednesday, December 12, 2018. Mr. Margolis is scheduled to participate on a panel on Wednesday, December 12, 2018 entitled “The Funding Challenges Associated with Cannabis-Derived Pharmaceuticals.”

The slide presentations that the Company will be using at the conference are attached as Exhibits 99.1, 99.2 and 99.3. The press release announcing the Company’s participation in the conference is attached as Exhibit 99.4. These exhibits are being furnished and not filed to Item 7.01 of Form 8-K

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

A list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

EXHIBIT INDEX

* Furnished herewith.


RespireRx Pharmaceuticals Inc. Exhibit

To view the full exhibit click here

About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)

RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea.

An ad to help with our costs